Showing results (461-470 of 2,106) with videos related to
Sort By:
Pageof 211
CNS Drugs|October 8, 2025
Ethnicity-Based Personalized Clozapine Titration Strategies for Prevention of Clozapine-Induced Inflammation: Recommendations Based on Evidence from the Japanese PopulationYuki Kikuchi, Bunichiro Onodera, Hiroshi Komatsu, et al.CNS Drugs|August 13, 2025
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension TrialRobert L Findling, Alain Katic, Michael Liebowitz, et al.CNS Drugs|February 8, 2023
Daridorexant in Insomnia Disorder: A Profile of Its UseTina Nie, Hannah A BlairCNS Drugs|January 29, 2026
New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin LandscapeSusanne Englisch, Mathias ZinkCNS Drugs|February 12, 2026
Circadian Rhythm and Efficacy of Argatroban in Ischemic Stroke with Alteplase: A Post Hoc Analysis of the ARAIS TrialMing-Rui Chen, Fei Liu, Thanh N Nguyen, et al.CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.CNS Drugs|February 2, 2026
Tolerance and Tachyphylaxis to Medications for Attention-Deficit/Hyperactivity Disorder (ADHD): A Systematic Review of Empirical StudiesChristopher Smith, Hollie Walker, Valeria Parlatini, et al.CNS Drugs|June 7, 2025
Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment for Severe Opioid Use DisorderAdrian Guessoum, Severin B Vogt, Maximilian Meyer, et al.CNS Drugs|April 1, 2025
Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy GrailÉmile Breault, Rebecca L Brouillette, Terence E Hébert, et al.Pageof 211